Granules India Limited — PPTs, 24-01-2025: Investor Presentation

Granules India Limited has provided an update regarding its operational developments and financial performance for Q3 FY25. The company voluntarily paused production at the Gagillapur facility in September 2024 due to US FDA observations but has since resumed operations in a staggered manner. Financially, the company achieved revenue of ₹11,377 Mn, reflecting a 61.7% year-on-year growth. Strong gross margins were sustained at 61.7%, bolstered by an increase in finished dosage sales. However, challenges persist in the API/PFI segments due to price erosion and high inventory levels among customers, leading to a decrease in their contribution.

The company also reported robust cash flow from operations at ₹1,301 Mn, maintaining a healthy Net Debt to EBITDA ratio of 0.90x. Significant product approvals were received for new formulations, including Bupropion SR and Lisdexamphetamine. Looking ahead, investors should watch closely as Granules navigates the competitive landscape and adapts to operational challenges while expanding its product range, indicating a positive outlook.